A Study to Evaluate Long-term Safety and Clinical Activity of ALN-AS1 in Patient With Acute Intermittent Porphyria (AIP)

Condition:   Acute Intermittent Porphyria Intervention:   Drug: ALN-AS1 Sponsor:   Alnylam Pharmaceuticals Enrolling by invitation - verified October 2016

Source: ClinicalTrials.gov - October 28, 2016 Category: Research Source Type: clinical trials